| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2024 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 2,000 | $0.13 | $267.50 | - | - | - | |
| May 21, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 45,031 | $18.20 | $819,732.28 | -6.7% | -5.7% | +230.3% | |
| May 20, 2024 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | CMO,SVP,Head-res&Drug | Sell | 16,128 | $6.45 | $104,025.60 | -3.8% | -25.9% | -89.8% | |
| May 20, 2024 | IRWD Ironwood Pharmaceuticals Inc | Davis Andrew73 | SVP, Chief Business Officer | Sell | 22,725 | $6.45 | $146,576.25 | -7.3% | -25.9% | -89.8% | |
| May 20, 2024 | BCRX Biocryst Pharmaceuticals Inc | Hutson Nancy J58 | Director | Buy | 5,000 | $6.38 | $31,900.00 | +6.1% | +28.2% | +68.5% | |
| May 20, 2024 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 67,618 | $6.45 | $436,136.10 | -5.6% | -25.9% | -89.8% | |
| May 20, 2024 | BCRX Biocryst Pharmaceuticals Inc | Milano Vincent | Director | Buy | 15,000 | $6.25 | $93,750.00 | +28.8% | +28.2% | +68.5% | |
| May 20, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 4,915 | $20.01 | $98,372.74 | -3.0% | -11.0% | +229.1% | |
| May 20, 2024 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 12,855 | $61.81 | $794,567.55 | -1.7% | -0.8% | -1.8% | |
| May 20, 2024 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 17,404 | $6.45 | $112,255.80 | -5.6% | -25.9% | -89.8% | |
| May 20, 2024 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 197,408 | $0.16 | $31,585.28 | +0.1% | - | - | |
| May 17, 2024 | SCLX Scilex Holding Co | Ji Henry | Executive Chairperson | Buy | 50,000 | $0.88 | $43,985.00 | +71,429% | +37.8% | -86.6% | |
| May 17, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 943 | $14.50 | $13,673.50 | -100% | +7.8% | +343.7% | |
| May 17, 2024 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 192 | $2.48 | $476.74 | -0.1% | -16.5% | -66.0% | |
| May 17, 2024 | NBIX Neurocrine Biosciences Inc | Norwalk Leslie V64 | Director | Sell | 1,106 | $141.82 | $156,849.93 | -52.7% | +3.9% | -14.9% | |
| May 17, 2024 | NBIX Neurocrine Biosciences Inc | Sharp Shalini | Director | Sell | 1,106 | $141.90 | $156,943.39 | -52.7% | +3.9% | -14.9% | |
| May 17, 2024 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 2,100 | $141.84 | $297,860.43 | -6.2% | +3.9% | -14.9% | |
| May 17, 2024 | SCLX Scilex Holding Co | Ma Stephen Hoi | Chief Financial Officer | Buy | 14,140 | $0.88 | $12,443.20 | New | +37.8% | -86.6% | |
| May 17, 2024 | SCLX Scilex Holding Co | Chun Jay | Director | Buy | 57,500 | $0.90 | $51,640.75 | +127.8% | +37.8% | -86.6% | |
| May 17, 2024 | AMRX Amneal Pharmaceuticals, Inc. | Autor Deborah M. | Director | Sell | 38,000 | $6.74 | $256,106.25 | -15.3% | +16.0% | +11.4% | |
| May 17, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Director | Sell | 7,200 | $272.82 | $1,964,298.92 | -37.7% | +17.8% | +11.3% | |
| May 17, 2024 | SCLX Scilex Holding Co | Shah Jaisim | See Remarks | Buy | 140,000 | $0.87 | $121,945.18 | +121.9% | +37.8% | -86.6% | |
| May 17, 2024 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 37,145 | $64.37 | $2,391,120.80 | -1.6% | -0.5% | -2.3% | |
| May 16, 2024 | TCNNF Trulieve Cannabis Corp. | Alvarez Giannella | Director | Sell | 1,072 | $12.76 | $13,677.54 | -2.3% | - | - | |
| May 16, 2024 | ANIP Ani Pharmaceuticals Inc | Tannenbaum Renee P55 | Director | Sell | 2,000 | $63.87 | $127,740.00 | -9.9% | -7.2% | -5.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.